Abivax (ADR) (ABVX)
Develops oral obefazimod for ulcerative colitis and Crohn's disease.
Something off on this page? Send us feedback.
Develops obefazimod, an investigational oral small molecule for inflammatory diseases, initially for moderately to severely active ulcerative colitis. The clinical-stage business is concentrated in obefazimod, with ulcerative colitis and Crohn's disease clinical programs.
Develops obefazimod, an investigational once-daily oral small molecule for inflammatory diseases. Its first intended use is moderately to severely active ulcerative colitis.
The program is built around enhancing miR-124 expression in immune cells. ABTECT is the Phase 3 ulcerative-colitis program, while ENHANCE-CD is a Phase 2b Crohn's-disease trial.
Founded in Paris, the clinical-stage company operates across France and the United States through a dual Euronext Paris and Nasdaq listing.
Its concentrated model depends on clinical-data interpretation, regulatory decisions, continued funding, and license rights from CNRS, the University of Montpellier, and Institut Curie.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 22, 2026 | Wedbush | Target | Target: $90 | Target: $118 |
| Sep 22, 2026 | Truist Financial | Target | Target: $155 | Target: $151 |
| Sep 9, 2026 | Goldman Sachs | Initiate | Rating: —Target: — | Target: $155 |
| Jul 24, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $132 | Target: $180 |
| Jul 9, 2026 | Piper Sandler | Reiterate | Rating: —Target: $142 | Target: $175 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $607.1M · Total debt $52.5M · Total assets $746.7M · Shareholders' equity $521.0M
- Revenue
- $0
- Operating income
- −$228.5M
- Net income
- −$329.4M
Reported in EUR, converted at the latest exchange rate
No dividends on record.
| Institutions | ≈ 67.92% | 53.34M ADS | |
|---|---|---|---|
| 367 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 5.00% | 3.92M ADS | |
| 1 holder · as of Feb 13, 2026 | |||
| Strategic holders | 8.22% | 6.46M ADS | |
| 1 holder · as of Nov 14, 2025 | |||
| Other | ≈ 18.86% | 14.82M ADS | |
| remainder | |||
78.54M ADS as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
TCG Crossover GP I, LLCStrategic | 8.22% | 6.46M | filed Nov 14, 2025 |
TCG Crossover Management, LLCInstitution | 7.65% | 6.01M ADS | as of Jun 30, 2026 |
Invus Public Equities, L.P.Insider | 5.00% | 3.92M | filed Feb 13, 2026 |
Darwin Global Management, Ltd.Institution | 4.61% | 3.62M ADS | as of Jun 30, 2026 |
Helikon Investments LtdInstitution | 3.55% | 2.79M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- AbbVie
Oral advanced UC overlap through RINVOQ
- Pfizer
Oral UC overlap through VELSIPITY
- Bristol-Myers Squibb
Oral UC overlap through ZEPOSIA
- Eli Lilly
Advanced UC and Crohn's overlap through OMVOH
- Takeda (ADR)
Advanced UC and Crohn's overlap through ENTYVIO
- Johnson & Johnson
Advanced UC overlap through TREMFYA
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Abivax (ADR) | $98.30 | +0.03% | $7.60B | — | — | — | +3.7% |
| AbbVie | $265.04 | −0.09% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| Pfizer | $27.91 | −0.07% | $158.10B | 36.7 | 10.0 | 2.5 | +2.6% |
| Bristol-Myers Squibb | $62.25 | +0.01% | $127.91B | 13.8 | 9.7 | 2.6 | +5.7% |
| Eli Lilly | $1,171.63 | +0.10% | $1.10T | 39.1 | 28.6 | 13.8 | +47.7% |
| Takeda (ADR) | $18.89 | −0.34% | $60.11B | 52.5 | 59.9 | 2.0 | +4.2% |
| Johnson & Johnson | $269.61 | +0.12% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Median | 37.9 | 20.1 | 4.6 | +6.2% |